Newron Pharmaceuticals — A defining year ahead for evenamide
Newron Pharmaceuticals has reported its FY25 results, ahead of what will be an important year for lead asset evenamide in treatment-resistant...
363 Views
Newron Pharmaceuticals — €38m raise to support ENIGMA-TRS
Newron Pharmaceuticals has announced an equity issuance of up to €38m with a group of existing and new shareholders from Europe and Asia. Proceeds...
221 Views
Newron Pharmaceuticals — Phase III ENIGMA-TRS 2 trial underway
Newron Pharmaceuticals has announced the launch of its Phase III ENIGMA-TRS 2 trial in the US, marking an important step for the registrational...
246 Views
Newron Pharmaceuticals — H125 results reflect evenamide progress
H125 saw Newron Pharmaceuticals make significant clinical headway with lead asset evenamide, culminating in the initiation of the first Phase III...
317 Views
Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment
Newron Pharmaceuticals has confirmed that enrolment has begun for its registrational ENIGMA-TRS Phase III programme for lead candidate evenamide....
259 Views